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Abstract  
 
This paper examines the ‘technological appraisals’ carried out by NICE (National Institute for 
Health and Care Excellence) as it regulates the provision of expensive new drugs within the 
English NHS on cost-effectiveness grounds. Ostensibly this is a highly rational process by 
which the regulatory mechanisms absorb uncertainty but in practice decision-making 
remains highly complex and uncertain. This paper draws on ethnographic data – interviews 
with a range of stakeholders and decision-makers (n=41), observations of public and closed 
appraisal meetings, and documentary analysis – regarding the decision-making processes 
involving three different pharmaceutical products. The study explores the various ways in 
which different forms of uncertainty are perceived and tackled within these Single 
Technology Appraisals (STAs).  Difficulties of dealing with the various levels of uncertainty 
were manifest and often rendered straightforward decision-making problematic. 
Uncertainties associated with epistemology, procedures, interpersonal relations and 
technicality were particularly evident. The need to exercise discretion within a more formal 
institutional framework shaped a pragmatic combining of explicit and informal, collective 
and individual, strategies and tactics to navigate through the layers of complexity and 





The National Institute for Health and Care Excellence (NICE) which was set up in 1999 in 
England typifies the shift towards pursuing ‘neutral’ and ‘objective’ regulation which has 
recently characterised British governmental institutions.1 Through systematic appraisals of 
the cost and clinical effectiveness (cost utility) of various expensive drugs for the NHS, NICE 
was designed to overcome the inconsistencies of the previously ad-hoc and implicit 
discretionary decisions of local clinicians2 – replacing this with explicit, evidence-based 
decisions which regulate NHS prescribing. Though only one of several functions carried out 
by the institute,3 drug appraisals are the most prominent and publicly scrutinised.4 Decisions 
are considered, at least in part, in the public arena which is believed to enhance 
transparency and provide legitimacy to the policy process of rationing health care 
technology.5   
From an ethical perspective, the role performed by NICE is intended to assure consistently 
equitable access for patients to drugs across the NHS and to facilitate the efficient use of 
public finances, by regulating NHS consumption of new and expensive drugs using cost-
effectiveness criteria.4,6,7 Based on rigorous appraisals of scientific evidence, NICE seeks to 
manage uncertainty through a calculative and evidence-based approach, amidst increasing 
cultural expectations of a ‘calculability of consequences’.8 This portrayal of the rationing 
process might be seen to reflect both instrumental and institutional forms of rationality.9 
Yet behind this discourse or policy talk10 of objectivity and rationalism in the pursuit of 
explicit rationing, the influence of socially-constructed assumptions and subjectivity may still 
prevail.11,12 
Evidence from statistical analyses suggests that while the demonstration of clinical and 
economic value is central to NICE decisions, the variability in these decision-outcomes about 
 3 
 
whether they recommend a technology or not can also be explained by other process and 
socio-economic factors.13  This may be due, at least in part, to the very nature of 
bureaucratic judgements amidst uncertainty, where reliance on – and correspondingly trust 
in – people and systems is unavoidable.14 Whether it is confidence in research paradigms 
and approaches, trust in expert panels, or weighing up the evidence presented by different 
expert patients, leading clinicians, or drug company representatives – a range of socially-
constructed assumptions, might influence attributions of validity, competency and/or 
motives,15  which could bear decisively on appraisal decisions.16 There is explicit recognition 
by NICE that so-called ‘gut’ components might be important in disinvestment decisions17 
and more recently NICE has formally introduced further prioritisation criteria, in addition to 
its threshold of cost- effectiveness based on social value judgements which include severity 
of underlying condition, unmet need, significant innovation, wider social benefit, 
disadvantaged populations and children.18,19 Such pragmatism might be a reaction to media 
pressure,20 legal challenges21 unrepresentative minority interest group lobbying,22 and the 
challenging of NICE decisions by agreements made directly between the manufacturer and 
the Department of Health.2,3,4 This reactive behaviour by the regulator (NICE) makes evident 
the poly-centric nature of the regulatory regime and may also reflect the influence of 
interest groups such as NHS clinicians, patient groups and of the pharmaceutical industry 
with the associated claims of corporate bias and regulatory capture.4 The impact of these 
and related factors within the appraisal process, and their potential influence on the 
intuition based ‘gut components’ of decisions, might be obscured by the ostensible 
rationality of NICE as an institution which formally attempts to absorb uncertainty through 




Uncertainty in this type of rationing and regulatory context has been portrayed in different 
ways, with one approach suggesting the need to recognise but minimise it23 and another 
suggesting the exploration of uncertainty should be portrayed in a more positive light as a 
means of making rationing decisions more transparent, accountable and democratic.21 
Uncertainty has been broadly defined as ‘the normal determinant or unsettled quality of a 
statement or knowledge claim’.21 The extent and the different forms of uncertainty faced by 
clinicians during medical training /socialisation24 and how these are managed in clinical 
decision-making are well documented25 and there are sociological studies which have 
examined how uncertainty in rationing decisions is negotiated.21 In addition, a number of 
ethnographic studies of rationing decisions have been carried at the local level26,27 which 
have identified the use of different forms of rationality although these studies have not 
specifically acknowledged the salience of uncertainty or the different ways it may become 
manifest. The aim of this paper is to fill this gap by unpacking the concept of uncertainty by 
focusing on two interrelated questions – pertaining to different forms of uncertainty and 
different strategies amid such uncertainties:  
 
The first question aims to identify which forms of uncertainty are evident in NICE appraisal 
committee decision making? The conceptual approach adopted in this research was 
informed by a content analysis carried out on NICE documents (Authors) relating to 
technological evaluations. This analysis identified three distinct layers or forms of 
uncertainty which might be manifest within NICE appraisals which are epistemic, procedural 
and interpersonal or relational. The aim is to assess the explanatory power of this 
developmental framework based on documentary analysis and to see if these and other 
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forms of uncertainty are manifest and salient in decision-making analysed via ethnographic 
data.28 
Within this framework, epistemic uncertainty relates to the effectiveness of certain methods of 
investigation to provide knowledge about conditions and their treatment. This layer of 
uncertainty might involve at least two aspects: confidence in the system of bio-medical 
knowledge24 and especially in the approach of randomised controlled trials29 and confidence in 
the publication system of medical journals to differentiate reliable (published) studies from 
biased (non-published/manufacturers’) data.30,31 The second layer of uncertainty is procedural – 
involving the various possible methods and approaches9 to considering/modelling quality of life 
and related features of effectiveness, the vast amounts of evidence which could be considered,24 
and the multiple contingencies and contestable outputs associated with these. The third layer of 
uncertainty is interpersonal or relational – regarding the competency and motives of those 
providing evidence and/or recommendations within the process. Uncertainty may exist due to 
diverse perspectives and relative expertise32 of an array of participants, but furthermore due to 
the interests that certain groups (eg manufacturers’ representatives) have in the outcome of the 
decision-making process32. 
The second main question explores which mechanisms and/or strategies, if any, are used to 
address or bridge over these various uncertainties? Sociological research into rationing decisions 
at the national level appears to have paid rather limited attention to differentiating between 
different forms of uncertainty and how these are managed.21 More generally, however, Zinn33 
has described strategies such as emotion, rules-of-thumb, and intuition, as lying ‘in-between’ 
rational (calculative and probabilistic) and non-rational strategies (belief, trust, hope, faith and 
avoidance) for dealing with uncertainty.34,35 The aim is to explore the relevance and salience of 
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these various strategies for managing uncertainty within NICE appraisal decision-making as they 
are applied in the face of different forms of uncertainty. 
 
Methods  
Characterising the Single Technological Appraisal (STA)    
The STA process for each technology is instigated by the Department of Health in 
negotiation with NICE and begins with the formulation/initiation of a decision-problem and 
decision-criteria followed by a review of evidence. The STA process relies on manufacturer-
provided information13 so the modelling of clinical and cost effectiveness by pharmaceutical 
companies informs the formulation of an incremental cost effectiveness ratio (ICER or 
cost/QALY).  Independent academic units or ‘evidence review groups’ (ERG) then appraise 
the drug manufacturer’s (DM) submission along with official feedback statements from 
expert/professional organisations, patient groups and other interests. The committee is 
made up primarily of experts in medical statistics, health economics, epidemiology, public 
health, clinical specialisms (nurses and doctors), representatives from the health service, the 
pharmaceutical industry and the (lay) public. Each member (apart from the chair) is 
appointed on an unpaid voluntary basis. A number of open and closed sessions of 
committee meetings take place and decisions are (usually) explicitly agreed in the meeting, 
on the basis of the cost effectiveness threshold (the ICER must be £20,000-£30,000 or less). 
This threshold has become an explicit and formal norm but appears not to have a rational 
basis. Decision making is primarily consensual although on some occasions voting is used in 
the last resort.    
Meeting outcomes are formulated into an appraisal consultation document (ACD) which, is 
further scrutinised and following further meetings (where necessary) a Final Appraisal 
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Determination(FAD) is published.17 Ideally, our study would have included all phases of the 
appraisal process, but this was not feasible (access, timing) so this investigation focused on a 
significant part of this process - following the various committee meeting stages through to 
the finalisation of the decision. However, an interview with the chair of the committee was 
carried out prior to the first committee meeting for each specific case but directly after the 
chairs’ briefing meeting, to which we could not gain access. These interviews gave us 
important insights into the earlier stages of each appraisal.  
 Design:  The study used a prospective design to follow three different pharmaceutical 
products through STAs involving three of the four NICE technological appraisal committees.  
Products were purposively selected for variation in the socio-cultural resonance of the 
condition they are designed to treat: a drug treating a common type of life-threatening 
illness, a drug treating a less ‘prominent’ but prevalent chronic illness, and a drug which 
treated a rare but life-threatening condition. Ten committee meetings were necessary to 
appraise the three case study technologies and the outcomes of the decision-making for the 
three technologies was one recommendation of a conditional ‘yes’ and two ‘no’s. None of 
these appraisals involved an appeal although one went through discussions regarding the 
discounting or patient access scheme (PAS). 
Data collection: The research used an ethnographic approach to understand the decision 
making process from the perspective of those under study.36,37 Data were collected through 
three different but complementary methods: analysis of documents; non participant, 
unstructured observation of the meetings; and qualitative, semi-structured interviews with 
key informants involved in the appraisal process. These data were used in triangulation with 
one another, comparing how uncertainties and decisions were written about, and how they 
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were recounted in interviews, with what was observed in meetings – to cover different 
perspectives and features of the appraisal processes.38  
Analysis of documentary outputs of the appraisal process provided a detailed background 
for understanding the decision – and therefore facilitates comparison with the ‘back-stage’ 
process as elucidated through observations and interviews.  Documents made publicly 
available by NICE were examined alongside those exclusively available to the committee, 
such as the drug manufacturers’ submissions.  Observations were carried out at the public 
and closed sessions of nine of the ten committee meetings (alongside three pilot 
observations) where decisions were made - generating data for analysis in their own right as 
well as foci for discussion within the interviews.  Ethical approval from the University of Kent 
was received in 2011 and those who consented were interviewed and/or observed. Pilot 
interviews and extensive observational work were carried out to refine the methodology. 
Across each drug appraisal, semi-structured interviews were conducted with a purposive 
cross-sectional sample (N=41) including the committee members (CM), representatives 
from the various interest groups, experts involved in the process and managers from NICE 
(see table 1), complemented by observations across the three case studies (N=9). Generally, 
the focus of the interview was on the structure and nature of the decision making process 
and what shaped it, with the salience of uncertainties and how these were managed being 
explored within the more general context.   More specifically, the topic guide included 
broader themes associated with individuals’ history and experiences, social relations within 
the meeting and the social mechanisms and influences which might shape the decision-
making from the wider social, cultural environment. The field work was carried out between 




                                           Insert Table 1 here 
 
Analysis: Analysis of uncertainty within and across the three cases can be described as 
abductive,39 in that some of the themes had already been considered prior to the study as 
informed by the initial analytical schema but this did not preclude the identification of other 
forms of uncertainty. The themes which emerged from the qualitative data were used to 
refine, challenge and extend an awareness of the different aspects of uncertainty that are 
faced by actors within the appraisal process and moreover the strategies applied (explicitly or 
implicitly) in the face of these. Different dimensions of uncertainty were categorised into 
themes and sub-themes through a constant comparison approach.40 The data were coded 
separately by two of the research team and samples of the data were double-coded and 
discussed to advance reliability and construct validity. Data from the observation and 
interviews were pooled and compared, with NVIVO being used to aid the analysis.  
 
Findings 
The analytical purchase of the conceptual framework 
The conceptual framework was based on documentary analysis but did it still have explanatory 
value given the different sources of data used in this analysis which were drawn from observation 
and interviews? The relevance and importance of uncertainty at a general level were recognised 
by all the informants, with those on the committee seeing it as central to the decision-making: 
        ‘There’s lots of tension between the group because some will say, “No, this is really good.”, 
“Look at the benefit it will bring to patients,” and then others will say, “Yes, but it’s far too 
expensive.  How can we think about that and how do we know that the quality of life data is as 
accurate as the manufacturers say it is?”  So, yeah, I found that there was lots of uncertainty.’  




The framework distinguished, however, between three different elements, epistemic uncertainty, 
procedural uncertainty and interpersonal uncertainty-each of which were evident in the data and 
salient to the participants, although other elements such as complexity were equally relevant.  
Epistemic uncertainty: 
Epistemic uncertainty relates to the basic effectiveness of particular methods of investigation to 
generate useful knowledge/data about illness experiences and treatment. Certainly the quality of 
the evidence base was a common theme of concern, the methods and status of randomised 
controlled trials were sometimes contested (eg the example of cherry picking below) and the 
quality of the trials was seen to be problematic. However, the lack of mature data was seen to be 
one of the key sources of epistemic uncertainty which is illustrated in the following extract drawn 
from observations made in one of the meetings for a TA which was being considered for the PAS 
(discount scheme) but where ‘newly surfaced uncertainties’, which had previously remained 
dormant, posed problems for the committee, such as the uncertainty regarding longevity:  
Committee Member (CM) 1: we are asked to make a decision with inadequate data 
CM 2: the original decision of £---- was made with so much uncertainty .. I would like more 
time 
CM 3 : the age of the elderly patients is a big concern …we are making extrapolations from 
16 week data and we are now making decisions about 32 months. The uncertainty involved 
fills me with horror’. Open meeting Observation notes, case study Z 
The data below are from later on in the meeting in the closed session:  
CM 1: if its £--- and then we get away with a lot of uncertainty as it is so far from the 
threshold, but once it becomes closer to our threshold…’ 
CM 2 : what did we say about the comparability of the trial to the population to UK patients? 
 CM 3: refers to the article published about the trial  .. maybe they cherry picked that 
population? 
CM4:  all trials cherry pick their participants, but normally it does not matter (for cost-
effective calculations) but in this example it does’ 
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Chair: we are very uncertain about benefit in the long term. Nobody wants to say yes … the 
new ICER [incremental cost-effectiveness ratio] has new uncertainty and that the benefit is 
for fitter patients.’ Closed meeting: Observation notes case study Z 
 
 
Confidence in journal publication processes and the quality of data also spontaneously emerged 
within committee discussions, such as here in the context of a committee member discussing the 
role of the ERG who were also perceived to be influential:  
‘the quality of the critique by the evidence review group,  bringing out points about 
the original clinical trial of the data that really could put into question the validity of 
some of the conclusions, and this has been an extraordinary eye opener to me 
because it makes me look at these very high impact factor, high profile publications 
in a different light; wondering even why these publications actually got through to be 
published’. Clinical expert Z06  
 
 
The lack of quality data, but also understandings of the implementation costs, could also be 
seen to be problematic: 
‘There’s often a poor understanding of the costs of the treatment and particularly of 
the sort of implementation costs, so there’s always a huge uncertainty’. Committee 
member Y10 
 
The limitations of the evidence base due to constraints in carrying out clinical trials was 
particularly evident in relation to certain social groups such, as younger children:  
  
‘ I’m personally softer at the edges around childhood illness – whether the committee 
as a whole is I don’t know. You know, there’ll be people who argue for a very rigid 
approach. It’s confounded by the fact that the evidence base for childhood diseases is 
usually weaker because randomised trials are much more difficult to arrange 
...children are generally well and therefore only ill in smaller numbers isn’t such a 
damaging thing for the NHS’. Committee member Z01 
 
Thus, in response to the epistemic concerns, other social, cultural and logics of rationing 





Procedural uncertainty and the problem of complexity  
  
The preliminary conceptual framework indicated that procedural uncertainty involved the 
multiple contingencies associated with various approaches to modelling effectiveness, the 
contestable and conflicting outputs of many of these, alongside the sheer volume of evidence 
which could be considered. 
The volume of information was a recurring and major issue for both committee members and for 
those who were invited to attend specific appraisals. Thus, doubts were expressed over whether 
the complete story could be comprehended given the sheer bulk of the information that needed 
to be digested. 
‘undoubtedly what has happened in the ten years that I’ve been on the committee is, 
the reports have got much bigger.  The serious point is that science is very 
complicated, there are an awful lot of uncertainties ‘. Committee member Y11  
 These challenges were compounded by the specialised and technical nature of the information 
provided, particularly the modelling for cost effectiveness or decision modelling. Thus, this issue 
appears to be related to both complexity (having too much information) and uncertainty (not 
knowing). The following observational extract illustrates this:   
‘CM1: the evidence is remotely realistic. The modelling is so complex and difficult that I’m 
not sure if it does anything or not 
CM2: this drug seems to work. It’s not that different from other treatments, but if we do a 
reality check. It’s not that expensive as current therapies 
CM3: that’s a pragmatic approach. I don’t know what the cost effectiveness is.  
CM4: I have concerns about the quality of the data which is poor as well as contentious 
CM5: it is safe. It’s not our remit 
Chair:  we are in a position of great uncertainty. I don’t have any sense whether the model is 
correct. The Decision Support Unit (DSU) needs to be convinced that the numbers run 
correctly, then look at it again. Can we phrase a Minded No [Interim decision in that there 




This last data extract raises the question of whether uncertainty was reduced during the 
course of the appraisal process. The contrary was found in some cases where epistemic 
uncertainties evolved into procedural uncertainty. For example, the following extract 
reflects the identification of additional sources of uncertainty from the experts during the 
discussion was perceived to have increased the uncertainties, resulting in a delay in the 
decision-making: 
 ‘In reality this drug probably should have gone through on the second appraisal 
[meeting] but we kept having this [newly emerging forms of] uncertainty thrown in’. 
Committee member X14 
 
The relationship between the independent assessment group (ERG) and the drug 
manufacturers was highlighted as a possible source of tension about access to information 
and uncertainty about what information should be available: 
‘The chair went on to discuss the ERG’s comments on the manufacturer’s submission 
and their re-analysis which led to an exchange and disagreement initiated by the 
chair between the manufacturer and ERG representatives over why the latter did not 
receive the analysis that they had repeatedly asked for and which the manufacturer 
said was not available’. Observation notes Case Study Y 
 
   
Interpersonal or relational uncertainty   
 
Interpersonal uncertainty was reflected in the perceived competency and motives of those 
providing evidence and/or recommendations within the process. This was relevant to a 
number of different interest groups who provided both written and oral submissions to the 
committee and, most commonly, the competencies and motives of the drug manufacturers, 
the nominated clinical experts and patient representatives. For example, in relation to the 
drug manufacturers’ position, common themes included concerns about bias and whether 
 14 
 
the drug manufacturers’ analysis could be trusted, resulting in limited confidence expressed 
in the submissions from the drug manufacturers: 
   Manufacturer representative: We didn’t understand the ERG’s point. We did the 
adjustment. 
   CM1,So you haven’t applied mortality from general life tables? 
   CM2, It’s not correct 
   CM3,It sounds like the company does know what it’s doing. I am mystified.  
One CM went on to suggest that the drug manufacturer should ‘give up and go home’ given 
the weaknesses in analysis and that their representatives were unable to answer some of the 
committees’ key questions. The representatives did not carry out the analysis themselves 
and were described by one member of the committee as ‘fall guys’. Observation notes Case 
Study X  
 
This case study illustrated a somewhat confrontational, becoming almost inquisitional,  
interaction between the committee and the drug manufacturers:  
‘I think [the committee] were getting very irritated because they didn’t have the 
answers that they wanted and at the end where they started really going for the 
manufacturers… I think the committee probably don’t trust them’. Clinical expert X02 
 
The reluctance to address at least some of uncertainties was perceived to be damaging for 
the drug manufacturers: 
 
‘I mean there’s lots of evidence on uncertainty that should be provided but the 
manufacturers still don’t give all of the information. I think one of the ways that we 
deal with that is that if there feels like there’s a lot of unresolved uncertainty then we’re 
more conservative in our estimate of what we think the ICER is going to be’. Committee 
member X08 
 
Finally, it was suggested that committee members’ uncertainty about and suspicion of the 
drug manufacturers had to be balanced against the level of criticism provided by the 
assessment groups: 
’One thing that’s really struck me about all of these appraisals, actually, is if you read 
the manufacturer’s submission, well, you should definitely fund this. They must be 
really trained to write it in such a way that, you know, it’s a done deal. But then you 
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read the ERG’s critique of it and you think oh, wait a minute!  And it makes you read 
it much more critically.  But then, you know, sometimes they’re over critical and it 
might be somewhere between the two’. Committee member Y12. 
The committee members also expressed ambivalence regarding the testimonies of both 
patient experts and clinical experts to the committee. There seemed to be a perception that 
patient representatives tended to be narrowly focused on their own condition and 
therefore provided a less balanced or broader view. Moreover, concerns were expressed 
about potential conflicts of interest as these patients were drawn from interest groups 
which were sometimes supported or paid by the drug manufacturers:  
‘It appears that many of these companies support these groups and at the beginning 
of every meeting everyone declares a conflict of interest…I’ve certainly been aware of 
it once where it was quite clear that a company was heavily supportive of the 
particular sort of patient support group and I found that quite difficult to be 
completely objective about… maybe the patients might be a bit naïve about some of 
the motivation but I think it is something you can’t really ignore. Committee member 
Z09. 
Similarly, uncertainties and ambivalences were expressed about the importance, 
competence and motives of the clinical experts, with some seeing these experts as 
importantly influencing later discussion: 
               CM ‘ I was  quite impressed at how the clinical expert was quite objective..’ 
Observation notes case study Y 
 
while others suggested a more marginal role:  
                ‘The role of the clinical expert, I think, is more to confirm any doubts in the 
submissions that the appraisal committee have. So I don’t think that clinical experts really 
would be ‘game changers’ under any circumstances’. Committee member Z05 
 
As with expert patients, there was a potential for clinical experts to be seen to be 
‘evangelists’, which raised the question of their independence as well as evidence of 
conflicted interests: 
             ‘occasionally you get some who seem to be very close to the manufacturer. [And so 





 Navigating or muddling through? 
Having considered the different types of uncertainty which appeared within the data, our 
analysis moves on to how these uncertainties were dealt with. A distinction can be made 
between explicit/formal strategies and/or mechanisms used by the committee and the 
informal strategies used by the committee both individually and collectively. The analysis 
shows how these personal practices used by individual members are organised into collective 
strategies adopted by the committee. 
   Explicit strategies included statistical and economic models available for denoting 
categories of uncertainty - particularly epistemic and procedural uncertainties - and thus 
attempts were made to technically measure and quantify the level and extent of confidence 
and uncertainty, although this did not necessarily solve problems of uncertainty. This 
perspective was evident in the following extract from an informant from NICE who suggested 
that they expected committee members to reflect on the epistemic and procedural 
uncertainties in the process: 
 
‘…we expect people to reflect on the uncertainty in the structure of the model, in the 
parameters used and the consequences of them.  There’s some different scenarios 
they could run and generally reflect on the timing at which the evidence has been 
created …probably the difficulties in understanding the natural history of patients 
without technology – all that stuff which is in the evidence – so there’s a technical 
way of expressing it. The challenge is to understand how committee deals with the 
uncertainty’ NICE Employee,03 
 
Informal strategies emerged due to the limitations of the explicit approaches.33 There was a 
recognition that some parts of uncertainty cannot be addressed and therefore tend to be ignored 
or bracketed off: 
‘I mean if you would take it [uncertainty] fully into consideration you basically can never 
take a decision because you just have to acknowledge that you don’t know, so every 
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decision’s constantly taken on the best available evidence and what you think is most likely 
so, yeah, part of that uncertainty is just brushed under the carpet’ Member of ERG Z02 
 
Thus, one individual practice involved focusing on certainties as opposed to uncertainties 
reflecting a form of bounded rationality: 
 
‘Rather than concentrate on everything that’s uncertain you say, “okay well what can 
we reasonably be confident about”, otherwise you only end up in a sea of uncertainty.’ 
Committee member.’ X03 
 
This type of pragmatic rationalism was a common stance which encompassed a number of 
personalised strategies: 
 
 ‘…but being pragmatic about it as well and just realise, okay, we don’t know but what is 
the objective here and try to keep sight of the goal…sometimes the economists on the 
committee lose this perspective’. Committee member X06 
 
One of these strategies appeared to involve invoking a subjective ‘gut ’feeling: 
 ‘ I think it comes down to a stance or gut feeling on how much you believe what’s in 
front of you’ Member of assessment group X05 
 
There were also pragmatic strategies employed to manage the quantity of information:  
‘I mean the last [appraisal] was horrible.   There were two thick volumes through each of 
the appraisals that we had which is why I think I’ve started working from the critique as it 
starts by summarising what they did’. Committee member Y12 
 
The level of complexity regarding the technicality of the information led to a lack of 
participation in discussion by non -technical specialists on the committee in what might be 
perceived to be an intimidating setting:  
‘Many members of the committee did not participate in the discussion as it was very 
technical and at one point the chair told one of the members to “please speak in 
‘plain English’”. One committee member commented: “I struggled today. there needs 




 Trust relations becoming salient in this context of complexity, where one common type of 
strategy used was to defer to the expertise and judgements of the specialists and others on 
the committee who were seen to have greater understanding of the complexity of the 
modelling (authors): 
           ‘So I have to take my thoughts on what I understand from the papers with a pinch of 
salt. You   need expert interpretation and guidance from the committee’. Committee 
member Y05  
 
This influence of particular experts within the committee in driving decisions was also 
corroborated by the observational evidence, with the case below reflecting deference to 
clinical judgement when there was considerable uncertainty about cost effectiveness:  
 
One committee member stated in the closed meeting that ‘there is uncertainty about 
the cost effectiveness so, rather than say ‘no’ to cost-effectiveness, we could say ‘no’ 
based on clinical guidelines if the committee is envisaging a role for this [drug] maybe 
the decision should not be just on cost effectiveness’. Hence, the uncertainty with the 
economic analysis led to the strategy to leave the decision to the clinicians - ‘let the 
doctors decide’ - so the decision followed the clinicians’ interpretation of NICE clinical 
guidelines. Observation notes Case study X. 
 
 
Committee members described being influenced by the committee discussion itself but also 
through informal discussions with other members of the committee, as a way of managing 
particularly the level of technicality of the information: 
‘…at committee some of the really in-depth economic analysis modelling discussions, 
for me, there’s that level of uncertainty…am I completely clear that I’m following 
everything that I should be?  What does tend to happen is the people who sit around 
you ask questions to one another.   “Did I hear that right?    You know, so there is a 
bit of informal reinforcement’. Committee member Z09 
 
One particular problematic area for the committee was dealing with the testimony of 
patient experts and contrasting collective strategies were used to manage these accounts 




‘Often that’s the last thing that happens at the end of part one [the public part of the 
meeting]is a speech by the patient group and I’m always a bit unsure of how I’m 
supposed to be processing that information and so it can sometimes be quite 
emotional…  I think the committee members deal with it in two ways; one is to 
completely dismiss the emotional arguments, or [be] completely dominated by them 
if we really understand the burden of this and the unmet need of the treatment...so 
it’s a tricky one’. Committee member Y12 
 
  
The analysis furthermore found that individual practices for dealing with uncertainty were 
coordinated into more collective strategies. For example, shared understandings of norms of 
which uncertainties could be questioned which could not, alongside the importance of 
deferring to the navigating role of the chair in bypassing uncertainties (‘the fudge factor’), 
were often referred to in interviews. These can be understood as a collective form of bounded 
rationality. For example, the chair could be seen to steer the committee towards what one 
committee member described as an efficient decision, as opposed to waiting for further 
evidence from the drug manufacturer or the specialist review groups which was seen as the 
easier option: 
‘a lot of that is to do with the experience of the Chair and the way of marshalling the 
contributions from the committee…there’s probably quite a lot of opt-outs that the 
committee could have along the way in terms of we want more information before we 
make a decision or we will go back and will we stall and require the manufacturer to 
do more? Will we want the ERG to do more analysis?’ Committee member Z12 
 
 
 Finally, a different collective strategy adopted by the committee took the form of an ongoing 
negotiating process with the drug manufacturers, involving demands for clarification over 
time. Hence, the latter depicted the appraisal process as a kind of game or strategy, whereby 
you initially submitted and were turned down and then resubmitted your work with the 
required outcome:    
 ‘I mean a ‘game’ probably makes it sound manipulative, but I suppose it’s just how it 
is, isn’t it, let’s have a similar scenario where the cost is quite high, which it often is, 
and then the benefit, the uncertainty around the evidence is very uncertain… Equally 
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it’s like getting your homework back and the teacher correcting it in the margin.  If 
you resubmit it with the corrections then you’ll get the A rather than the F you [were] 
predicted’.’ Drug manufacturer Z04 
  
The effectiveness of such a strategy was confirmed by a member of the committee when 
discussing the analysis provided by a drug manufacturer: 
‘The only thing that that could reduce the uncertainty will be head-to-head 
comparisons with hard endpoints…And that basically forces the manufacturer to 
provide further information…something like over 70% of Minded No’s become Yes 
when you get the information you actually want from them’. Committee member X 
01  
 
This ‘game’ format appeared to enable the gradual working through of uncertainty - getting 
the manufacturer to reduce the uncertainty and work through the most problematic issues. 
For example, in case Z the willingness of the manufacturer to do this and ‘play the game’ 
appeared influential in their new data/submissions being taken seriously. This appeared to 
be a kind of reciprocated ‘good will’, by which reducing interpersonal uncertainty enabled 




Sociological research into decision-making about rationing at the national level has to a 
limited extent focused on uncertainty,21 but not considered the different layers of 
uncertainty that might be embedded in these decisions and how they are managed. Thus, 
the focus of this analysis was on exploring the extent and nature of uncertainty in appraisal 
decision-making and how these uncertainties were addressed and managed in different 
ways.  The data analysis suggests that various intractable uncertainties were a significant 
and somewhat defining issue recognised by the informants from the committee – hence, 
the identification of a range of strategies used by the committee for dealing or grappling 
with these various types of uncertainty.   
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The loose conceptual framework constructed from the previous documentary analysis which 
distinguished between epistemic, procedural and interpersonal provided some analytical 
purchase in that there was evidence in the analysis of these three different elements of 
uncertainty. However, this schema did not fully capture the nature and experiences of 
uncertainty as they appear in the observational and interview data. Sometimes there was an 
overlap or blurring of the boundaries between categories.  For example, in relation to 
manufacturers’ submissions, there were uncertainties about the data used, procedures for 
analysing the data, the presentation of the data and the general motives and competence of the 
drug manufacturers’ stance by which epistemic, procedural and interpersonal uncertainty were 
interwoven with one another.  
There was also some evidence of shifts from one form of uncertainty to another as decision-
making processes evolved. For example, the data showed how issues of epistemic uncertainty 
evolved or were transformed into procedural issues as the committee deliberated on the 
evidence. Similarly, uncertainty about the quality of the drug manufacturers’ analysis, a form of 
procedural uncertainty, seemed to evolve into issues around trust in the drug manufacturers’ 
competence and motives - a form of interpersonal uncertainty. The types or layers of uncertainty 
identified in the analysis of publicly available, formal documents (Authors), tended to highlight 
issues around epistemic and procedural uncertainty rather than interpersonal uncertainty, which 
might reflect an emphasis within the front-stage policy talk about the instrumental and 
institutional approach of NICE.   However, the evidence from this ethnographic study which 
looked more at backstage decision-making suggests that forms of interpersonal or relational 
uncertainty are important and prevalent, particularly in relation to uncertainties expressed about 




Forms of uncertainty that the initial conceptual framework did not address included the level of 
technicality of the information provided, particularly in the modelling of the evidence, which led 
to the committee members being uncertain about its meaning and how to use it to come to a 
decision. This might be better described as complexity, whereby some authors41 argue that 
uncertainty is a residual of working with complexity, alongside related interpretative/valuing 
issues of ambiguity . Certainly, the extent of information provided seems to create further 
complexities rather than resolving uncertainty and straightforwardly facilitating rational decision 
making.42  
There was common recognition that some forms of uncertainty were ignored and not addressed, 
as they could not be managed and that, in order to reach a decision, deliberations ultimately 
needed to focus down on a relatively small number of issues, with wider potentially problematic 
uncertainties being bracketed off (Authors 2012). This reflected a form of reasoning characterised 
by bounded rationality and typifying a form of satisficing behaviour where this is seen as an 
acceptable, if not optimal, strategic solution43 – although in this context the evidence suggested 
forms of bounded rationality manifested in both collective and individual strategies. Collective 
strategies included: emergent norms by which the committee members learned to openly 
question some uncertainties while overlooking others; forms of collective deference to the chair 
or specific committee members with particularly high levels of expertise; or shared (mis)trust of 
particular manufacturers as their performances were evaluated during the appraisal. These 
collective strategies were thus comprised of ‘embedded’ organisational understandings44 which 
in turn involved an orchestration of many individual strategies,33 such as individual committee 
members’ trust in the chair or their committee ‘habitus’ as this emerged over time.  
There was evidence of a plurality of legitimate perspectives for evaluating evidence, decisions 
and outcomes but calculative approaches in NICE decision making were particularly emphasised 
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in the discussions on the strength of the evidence to support cost effectiveness13 and thus the 
uncertainties related to that issue were paramount. One primary concern was whether the drug 
manufacturers’ analysis had been carried out using the most appropriate methodology and 
addressed the salient pre-agreed appraisal questions and whether the submission was 
transparent and accessible enough to be critically assessed. Much emphasis was placed upon the 
drug manufacturers’ interpretations of the evidence and their tactics in presenting this, which 
might skew or shape the decision-making in favour of the drug manufacturer.13 However, the 
stance of the committees suggested that they were not passively accepting of this interpretation 
and could not be seen as simply aiding in so-called regulatory capture,4 at least at this micro-level 
of analysis.  
The interpersonal uncertainty associated with a lack of trust in the drug manufacturers’ 
competencies and motives led to a number of stances, strategies or tactics. One was a general 
scepticism adopted by the committee towards the drug manufacturers submissions requiring 
them to prove that their case was a genuine one. In response, the drug manufacturers pursued 
active strategies for dealing with the committee’s approach, one of which was to adopt trial and 
error tactics, with the hope that at the second or third attempt the technology would be 
recommended. 
    A similarly critical or ambivalent stance was adopted by the committees towards the 
testimonies of the patient and clinical experts as there was concern about the latter’s conflicts of 
interest, and possibilities of being ‘captured’ by the drug industry,22 or having too narrow an 
experiential focus rather than being concerned with what was best for the NHS patient 
population as a whole. The ambivalence or caution expressed about the opinions of these experts 
led their evidence to being used as supplementary or supportive information to the overall 
decision of the committee.  The relative influence of the experts varied from case to case, thus 
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there was only limited evidence in this study to support the notion of co-production of 
knowledge argued to be evident in the case study of dementia drugs.21   
      The stereotype of NICE as a procedurally-rational evidence-based regulatory institution 
contrasts with the somewhat messy process of committee decision making above; Mechanic’s 
description of muddling through elegantly is apposite here45. This was exemplified by the 
informal strategies used by individual committee members for dealing with residual uncertainty 
and aspects of complexity, particularly in relation to the technicality and sheer volume of 
information provided.  These strategies included developing rules of thumb, using ‘gut reactions’ 
based on intuitive/tacit knowledge and other ways of simplifying highly complex material. In 
some ways our findings reflected other ethnographic-oriented research focusing on rationing 
decisions at the local level which identified a related form of reasoning which is characterised as 
practical rationality and involves intuition and experiential knowledge9 and a ‘case and 
judgement based’ approach.26 In both contexts the use of practical rationality was evident but 
appeared to be at odds with the dominant instrumental discourse. In these local contexts ethical 
discussions and informal modes of dealing with uncertainty related more directly to individual 
circumstances.  
  In contrast, within NICE appraisals there appeared to be less space for individual discretion and 
a greater coordination of informal approaches through reference to norms and previous 
decisions, alongside a reliance and trust in those with specialist expertise, particularly senior 
clinicians and economists, to steer them in the right direction. These influential players on the 
committee were the clinicians, economists and statisticians, supported by the evidence review 
groups, who were most able to make sense of the technicality of the data analysis. Central to the 
coordination of informal approaches was the navigating role of the chairs and their ability to 
steer the committee through the complexity and even circumnavigate different aspects of 
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residual uncertainty - a form of collective bounded rationality, towards a collective decision 
within the time and space allowed in the institutional framework. However, such influences of 
intra-group dynamics and power relations, as well as (dis)trust, time limitations and a related 
bypassing of uncertainty, were invisible within the official, disembodied account of the FAD.10,27  
At a more global level, there is the general question about whether regulatory 
agencies operating in other countries with different health and welfare systems and cultural 
contexts approach their tasks in a similar or different way to how NICE works in England. 
Comparative analyses of how different regulatory agencies46 make recommendations about 
the provision of expensive medicines in the context of uncertainty are in short supply. 
However, at a more general level it appears that NICE might be more vulnerable to the 
influences of the pharmaceutical industry, compared with other regulatory agencies found 
in other contexts. For example, in New Zealand, PHARMAC (the equivalent of NICE) has 
become a Crown Entity, meaning that it is a standalone body and is independent from the 
influences and directions of government ministers, coupled with a set budget that it cannot 
legally exceed appears to make its less vulnerable to corporate bias47.  More generally, there 
seems to be this apparent paradox that regulatory agencies operating in the context of 
neoliberal health systems may be more able to resist the influences of the drug industry 
(regulatory capture) than those working in the context of more communitarian health 
systems. 48  
 
Limitations:  This study explored the decision-making across the three of the four 
committees which might be significant as it became evident that each of the committees 
appeared to have its own ‘style’ of decision-making heavily influenced by the chair, 
suggesting that there may be variations in recommendations by committee.  Cerri and 
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colleagues 13 found in their statistical analysis that a large majority of technological 
appraisals recommended ‘yes’ but the three cases followed in this current study involved 
two no’s and one conditional or restricted yes, suggesting that the appraisals included in our 
study might not be typical. However, in the pilot and feasibility stages of this research a 
number of other technological appraisal meetings were observed and the process, at the 
least, appeared to be similar to those that were observed in the main study. Moreover, 
statistical evidence13 suggest that the proportion of restrictions and non-recommendations 
issued by NICE are increasing although referral to discounting (via Patient Access Schemes 
and the recently abolished Cancer Drugs Fund) may have been increasing too23  
 
Conclusions 
Vast complexity and many uncertainties were central to these rationing decisions and the 
difficulties of dealing with the various levels of uncertainty were manifest. Decision-makers 
adopted a mixture of collective and individual, explicit and informal strategies in making decisions 
as there was a need to exercise discretion and pragmatism within a more formal institutional 
framework. Thus, rather than the decision-making process being neat and procedurally-rational, 
it was also characterised by a process of negotiation with the use of pragmatic methods to 
navigate through complexity and layers of uncertainty.  
The findings suggest that certain ‘social’ approaches to the appraisal process are gradually 
becoming institutionalized,37 either as unspoken norms within committees or more formally 
within the ‘methods’ guide for NICE appraisals. Not all categories of uncertainty have been fully 
recognised in current policy and this study showed the salience of uncertainties associated with 
interpersonal relations and particularly the relations between the committee and the drug 
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manufacturers, clinical experts and patient experts. These relations tend to be characterised in 
terms of trust or the lack of it.49   
Potential solutions to some of these problems raised by this study might include giving the 
committee a further decision outcome, such as ‘intolerable uncertainty’ or insufficient data which 
would assist in placing an onus on manufacturers to make their submissions as clear and 
transparent as possible. In addition, committee members might be given enhanced training in 
economics and statistics and more time for discussion, deliberation and preparation, the 
adoption of tighter controls on the conflict of interests of expert clinicians and a broader 
selection criteria for expert patients, rather than relying solely on recruiting from patient 
organisations. 
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Table 1: Type of informant interviewed  
Committee members including chairs1 N = 23 
Managers from NICE N = 3 
Patient organisations N = 3 
Drug manufacturers N = 5 
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Experts from assessment group/clinical experts N = 7 
Overall Sample  N= 412,3 
1 Includes statisticians, health economists, clinicians, public health epidemiologists and lay 
members.  2 Three with NICE staff plus 14 in case study X, 12 in case study Y and 12 in case study 
Z. 3 15 face to face and 26 telephone interviews.  
 
